NDAINJECTIONINJECTABLE
Approved
Apr 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NORCURON (vecuronium bromide) by Merck & Co. is clinical pharmacology vecuronium is a nondepolarizing neuromuscular blocking agent possessing all of the characteristic pharmacological actions of this class of drugs (curariform). First approved in 1984.
Drug data last refreshed 9h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORCURON (vecuronium bromide) is a nondepolarizing neuromuscular blocking agent used during anesthesia to induce skeletal muscle paralysis for intubation and surgical procedures. It works by competing for cholinergic receptors at the motor end-plate, antagonizing acetylcholine and preventing neuromuscular transmission. The drug is approximately one-third more potent than pancuronium with a shorter duration of action, making it suitable for intermediate-length surgical procedures.
LOE Approaching
Product lifecycle approaching loss of exclusivity; brand team likely focused on generic transition strategy and potential market contraction.
Mechanism of Action
CLINICAL PHARMACOLOGY Vecuronium is a nondepolarizing neuromuscular blocking agent possessing all of the characteristic pharmacological actions of this class of drugs (curariform). It acts by competing for cholinergic receptors at the motor end-plate. The antagonism to acetylcholine is inhibited…
Worked on NORCURON at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.